Last week’s San Antonio Breast Cancer Symposium featured new evidence* for a tool that might inform treatment decisions in women with low-grade breast tumors. Since the 1980s, diagnoses of DCIS (ductal carcinoma in situ) have risen dramatically due to enhanced screening. Questions about this condition – whether it’s likely to cause harm, and how to manage it – are central to debate about mammography, the concept of overdiagnosis, and overtreatment.
The investigators presented new results for Oncotype Dx (Genomic Health Genomic Health) a molecular pathology tool, for evaluating DCIS. The multi-gene DCIS assay yields a prognostic score for the likelihood that DCIS will recur or lead to invasive breast cancer.